ARS Pharmaceuticals, Inc. develops and commercializes neffy, an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis. The company’s news commonly covers U.S. commercialization, product labeling, international approvals and licensing relationships for neffy, which is marketed as EURneffy in the European Union and the United Kingdom and under a separate trade name in China.
Recurring updates also include quarterly and annual financial results, clinical and scientific presentations on intranasal epinephrine, school-access programs, manufacturing and supply responsibilities for partners, and investor conference activity. The company’s allergy-treatment focus makes regulatory decisions, product access, clinical data and commercial launch progress central themes in its public announcements.
ARS Pharmaceuticals (Nasdaq: SPRY), a company focused on protecting people from severe allergic reactions, announced its participation in the 2024 Wedbush PacGrow Healthcare Conference. The event will take place on August 13-14, 2024 in New York City. Company management will meet with investors on Wednesday, August 14, 2024, for one-on-one discussions.
This conference provides ARS Pharmaceuticals with an opportunity to showcase its work in empowering at-risk patients and caregivers against anaphylaxis. The company's presence at this healthcare-focused event could potentially attract investor interest and highlight its position in the biopharmaceutical sector.
ARS Pharmaceuticals (Nasdaq: SPRY) reported its Q2 2024 financial results and business highlights. Key points include:
1. neffy® (epinephrine nasal spray) NDA under FDA review with PDUFA date in early October 2024.
2. EURneffy® recommended for approval by EMA's CHMP, with formal marketing authorization expected in Q3 2024.
3. Outpatient study of neffy for urticaria set to begin in Q4 2024.
4. $218.7 million in cash and equivalents as of June 30, 2024, providing at least three years of operating runway.
5. Q2 2024 net loss of $12.5 million, compared to $17.4 million in Q2 2023.
6. R&D expenses decreased to $6.9 million, while G&A expenses reduced to $8.9 million in Q2 2024.
ARS Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of EURneffy (adrenaline nasal spray) for emergency treatment of allergic reactions, including anaphylaxis, in the European Union. This decision marks EURneffy as potentially the first and only needle-free adrenaline option in Europe. The positive opinion is based on extensive data, including studies involving over 700 participants and 1,200 administrations, demonstrating its efficacy and safety. The European Commission is expected to grant formal marketing authorization in Q3 2024, with availability anticipated in Q4 2024. The U.S. FDA is reviewing the same data, with a decision expected by October 2, 2024.
ARS Pharmaceuticals reported progress in regulatory processes for neffy, an epinephrine nasal spray, with an anticipated FDA review completion by October 2024. The company submitted responses for NDA and MAA to FDA and EMA respectively. ARS is well-capitalized with $223.6 million in cash and securities as of March 31, 2024, supporting neffy's expected U.S. launch in the second half of 2024. Clinical expansion for urticaria is underway, along with partnerships for global commercialization. Financially, R&D expenses decreased, G&A expenses decreased, and the net loss reduced compared to the same quarter in 2023.
ARS Pharmaceuticals submitted the Day 180 response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and entered a license agreement with CSL Seqirus for commercialization in Australia and New Zealand. The CHMP opinion on neffy is expected in the second quarter of 2024, addressing all identified issues and including results from a repeat dose study and updated nitrosamine testing. CSL Seqirus will handle regulatory approval, reimbursement, and commercialization, while ARS Pharma will manage manufacturing and supply.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.